Abstract
Many studies report an overlap of MRI and clinical findings between patients with relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS), which in part is reflective of inclusion of subjects with variable disease duration and short periods of follow-up. To overcome these limitations, we examined the differences between RRMS and SPMS and the relationship between MRI measures and clinical outcomes 30 years after first presentation with clinically isolated syndrome suggestive of multiple sclerosis. Sixty-three patients were studied 30 years after their initial presentation with a clinically isolated syndrome; only 14% received a disease modifying treatment at any time point. Twenty-seven patients developed RRMS, 15 SPMS and 21 experienced no further neurological events; these groups were comparable in terms of age and disease duration. Clinical assessment included the Expanded Disability Status Scale, 9-Hole Peg Test and Timed 25-Foot Walk and the Brief International Cognitive Assessment For Multiple Sclerosis. All subjects underwent a comprehensive MRI protocol at 3 T measuring brain white and grey matter (lesions, volumes and magnetization transfer ratio) and cervical cord involvement. Linear regression models were used to estimate age- and gender-adjusted group differences between clinical phenotypes after 30 years, and stepwise selection to determine associations between a large sets of MRI predictor variables and physical and cognitive outcome measures. At the 30-year follow-up, the greatest differences in MRI measures between SPMS and RRMS were the number of cortical lesions, which were higher in SPMS (the presence of cortical lesions had 100% sensitivity and 88% specificity), and grey matter volume, which was lower in SPMS. Across all subjects, cortical lesions, grey matter volume and cervical cord volume explained 60% of the variance of the Expanded Disability Status Scale; cortical lesions alone explained 43%. Grey matter volume, cortical lesions and gender explained 43% of the variance of Timed 25-Foot Walk. Reduced cortical magnetization transfer ratios emerged as the only significant explanatory variable for the symbol digit modality test and explained 52% of its variance. Cortical involvement, both in terms of lesions and atrophy, appears to be the main correlate of progressive disease and disability in a cohort of individuals with very long follow-up and homogeneous disease duration, indicating that this should be the target of therapeutic interventions.
Highlights
Clinical outcomes in multiple sclerosis are highly variable, develop over decades and to date no biomarker has been proven to robustly explain levels of disability, or to reliably distinguish between relapsing remitting (RRMS) and secondary progressive (SPMS) disease
Adjusting for age and sex, the distributions of clinical outcome measures were well separated between RRMS and SPMS cases, whilst they were largely overlapping between clinically isolated syndrome (CIS) and RRMS, with the exception of the 9-Hole Peg Test (9HPT), which was more abnormal in RRMS than CIS (Fig. 2 and Table 1)
Differences between RRMS and SPMS were found for cognitive outcome measures, including the revised BVMTR-z and Symbol Digit Modalities Test (SDMT)-z, which showed a greater abnormality in SPMS than RRMS (Table 1)
Summary
Clinical outcomes in multiple sclerosis are highly variable, develop over decades and to date no biomarker has been proven to robustly explain levels of disability, or to reliably distinguish between relapsing remitting (RRMS) and secondary progressive (SPMS) disease. In part this is likely due to previous studies assessing patients who were at different points in their multiple sclerosis disease course or were studied only for a short period of follow-up. Studies comparing patients with disease durations of less than two decades are likely to be hampered by a proportion of patients in the RRMS group who will eventually go on to develop SPMS,[1] and may already display biomarker features of progressive disease. Of those who developed SPMS, most converted within 20 years after symptom onset
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.